<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02530697</url>
  </required_header>
  <id_info>
    <org_study_id>40068714.1.0000.5558</org_study_id>
    <nct_id>NCT02530697</nct_id>
  </id_info>
  <brief_title>The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil</brief_title>
  <official_title>The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: An Open-label, Randomized Clinical Trial in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Brasilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Brasilia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries
      worldwide. The standard treatment with meglumine antimoniate has a high rate of important
      adverse effects. This interventional study consists in a randomized clinical trial to access
      efficacy and safety of the association of miltefosine and pentoxifylline compared to
      meglumine antimoniate and pentoxifyline.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure</measure>
    <time_frame>90 days</time_frame>
    <description>Complete healing of previous lesions until the 90th day after the begin of the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Failure</measure>
    <time_frame>90 days</time_frame>
    <description>Lesions fail to heal until the 90th day after the begin of the treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse</measure>
    <time_frame>90 days</time_frame>
    <description>Lesions that reappear on the scar of a previously healed lesion</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Group 1 - Mucosal Antimoniate and Pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days. Pentoxifylline 400mg 3x/daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Mucosal Miltefosine and Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily. Oral Pentoxifylline 400mg 3x/daily for 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Cutaneous Antimoniate and Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mgSb+5/kg/day meglumine antimoniate intravenous for 20 days Oral Pentoxifylline 400mg 3x/daily for 20 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 - Cutaneous Miltefosine and Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily Oral Pentoxifylline 400mg 3x/daily for 20 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meglumine antimoniate</intervention_name>
    <description>20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.</description>
    <arm_group_label>Group 1 - Mucosal Antimoniate and Pentoxifylline</arm_group_label>
    <arm_group_label>Group 3 - Cutaneous Antimoniate and Pentoxifylline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miltefosine</intervention_name>
    <description>Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.</description>
    <arm_group_label>Group 2 - Mucosal Miltefosine and Pentoxifylline</arm_group_label>
    <arm_group_label>Group 4 - Cutaneous Miltefosine and Pentoxifylline</arm_group_label>
    <other_name>Miltefosnine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.</description>
    <arm_group_label>Group 1 - Mucosal Antimoniate and Pentoxifylline</arm_group_label>
    <arm_group_label>Group 2 - Mucosal Miltefosine and Pentoxifylline</arm_group_label>
    <arm_group_label>Group 3 - Cutaneous Antimoniate and Pentoxifylline</arm_group_label>
    <arm_group_label>Group 4 - Cutaneous Miltefosine and Pentoxifylline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mucosal and/or cutaneous leishmaniasis, not treated or at least 6 months without any
             treatment to leishmaniasis;

          -  For patients with cutaneous lesions: duration of disease longer then a 1 month and
             shorter then 4 yeas; 1 to 3 lesions; larger lesions from 10mm to 50mm;

          -  Ages between 18 and 80 years old;

          -  Fertile female patients should use at least two contraceptive methods (hormonal and
             barrier);

          -  Agree to participate in the study and sign the informed consent term.

        Exclusion Criteria:

          -  Use of any leishmanicidal drugs six months prior;

          -  Clinical or laboratorial evidences of electrocardiographic disorders;

          -  Renal, hepatic, cardiac diseases, uncontrolled diabetes or AIDS;

          -  Hypersensitivity to meglucamine antimoniate;

          -  Pregnancy or lactation;

          -  Fertile females that do not agree to use contraceptive methods;

          -  Patients that do not agree to the informed consent term.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sofia S Martins, MD</last_name>
    <phone>+556120285415</phone>
    <email>sofiasalesm@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raimunda Sampaio, PhD, MD</last_name>
    <phone>+556120285415</phone>
    <email>raimunda.sampaio@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitário de Brasília</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <zip>70.840-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia S Martins, MD</last_name>
      <phone>+556120285415</phone>
      <email>sofiasalesm@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2015</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Brasilia</investigator_affiliation>
    <investigator_full_name>SOFIA SALES MARTINS</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Leishmaniasis</keyword>
  <keyword>Mucocutaneous</keyword>
  <keyword>Miltefosine</keyword>
  <keyword>Pentoxifylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
    <mesh_term>Leishmaniasis, Mucocutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miltefosine</mesh_term>
    <mesh_term>Meglumine Antimoniate</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

